Published in Diabetes Care on April 01, 2011
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia (2012) 3.70
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab (2014) 1.53
Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila) (2015) 1.49
The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care (2012) 1.42
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist (2013) 1.41
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol (2011) 1.21
Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol (2013) 1.09
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 1.03
Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control (2012) 1.01
Interpreting adverse signals in diabetes drug development programs. Diabetes Care (2013) 0.99
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig (2013) 0.98
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care (2013) 0.98
Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. J Gastroenterol (2012) 0.93
Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes Obes Metab (2014) 0.92
Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One (2014) 0.91
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine (Baltimore) (2016) 0.90
Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care (2011) 0.88
Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study. Diabetes Care (2012) 0.88
Pioglitazone: Indian perspective. Indian J Endocrinol Metab (2011) 0.88
Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 0.88
Inhibition of HDAC3 promotes ligand-independent PPARγ activation by protein acetylation. J Mol Endocrinol (2014) 0.86
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res (2015) 0.85
Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int (2015) 0.85
Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer. Rambam Maimonides Med J (2012) 0.82
Diabetes medications and cancer risk: review of the literature. Am Health Drug Benefits (2012) 0.81
Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Oncol Lett (2014) 0.80
Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer (2014) 0.80
Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside. PPAR Res (2012) 0.80
Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Res Care (2015) 0.79
Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. Aliment Pharmacol Ther (2016) 0.77
PPARγ in head and neck cancer prevention. Oral Oncol (2014) 0.77
Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders. Clin Med Insights Oncol (2015) 0.77
Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. P T (2012) 0.77
Association between diabetes or antidiabetic therapy and lung cancer: A meta-analysis. J Diabetes Investig (2013) 0.76
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus. Oncotarget (2016) 0.76
Why do anti-inflammatory therapies fail to improve insulin sensitivity? Acta Pharmacol Sin (2011) 0.76
Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PLoS One (2014) 0.75
Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study. BMJ Open Diabetes Res Care (2016) 0.75
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes Control (2016) 0.75
Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open (2017) 0.75
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Ethnic disparities in diabetic complications in an insured population. JAMA (2002) 8.28
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer (2005) 6.06
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care (1997) 3.17
Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res (2001) 1.96
Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1.79
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.65
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf (2007) 1.50
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat (2003) 1.39
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J Lipid Res (2002) 1.29
Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci (2005) 1.27
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med (2007) 1.16
Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer (2008) 1.14
Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J (2007) 0.99
Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res (2009) 0.97
Role of computerized physician order entry systems in facilitating medication errors. JAMA (2005) 26.32
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf (2007) 5.93
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA (2009) 5.75
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ (2005) 5.34
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Oral contraceptives and the risk of breast cancer. N Engl J Med (2002) 4.85
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol (2003) 4.27
Design of a national distributed health data network. Ann Intern Med (2009) 4.09
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
An increase in the incidence of gestational diabetes mellitus: Northern California, 1991-2000. Obstet Gynecol (2004) 3.77
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr (2002) 3.33
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation (2005) 3.28
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf (2005) 3.24
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Statin use and the risk of 10 cancers. Epidemiology (2007) 3.17
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med (2011) 3.12
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 3.06
Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage (2003) 3.05
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest (2005) 2.88
The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med (2006) 2.74
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry (2005) 2.60
Sexual activity and function in middle-aged and older women. Obstet Gynecol (2006) 2.59
Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS (2006) 2.57
Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr (2003) 2.55
Racial/ethnic variation in asthma status and management practices among children in managed medicaid. Pediatrics (2002) 2.54
Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53
Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol (2007) 2.53
Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA (2003) 2.51
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol (2009) 2.50
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ (2002) 2.46
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Use of abdominopelvic computed tomography in emergency departments and rates of urgent diagnoses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 2.40
Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol (2002) 2.39
Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control (2008) 2.35
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med (2005) 2.34
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation (2003) 2.32
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol (2010) 2.28
Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat (2007) 2.27
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23
Symptomatic pelvic organ prolapse: prevalence and risk factors in a population-based, racially diverse cohort. Obstet Gynecol (2007) 2.22
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21
The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol (2002) 2.21
Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res (2007) 2.19
Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation (2012) 2.19
Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med (2013) 2.16
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16
Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 2.15
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2002) 2.12
The impact of multimorbidity on sexual function in middle-aged and older women: beyond the single disease perspective. J Sex Med (2014) 2.12
Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol (2004) 2.11
White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research. Clin Transl Sci (2010) 2.09
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med (2007) 2.07
An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05
Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med (2010) 2.04
Urologic complications of diabetes. Diabetes Care (2005) 2.03
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis (2008) 2.03
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.02
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
Fecal incontinence in females older than aged 40 years: who is at risk? Dis Colon Rectum (2006) 2.01
Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00